XML 74 R64.htm IDEA: XBRL DOCUMENT v3.19.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Sep. 04, 2018
Aug. 08, 2017
Nov. 16, 2017
May 31, 2017
Oct. 25, 2016
Jun. 30, 2016
May 31, 2016
Dec. 31, 2015
Jan. 31, 2015
Sep. 30, 2014
Dec. 31, 2018
Dec. 31, 2017
Operating lease periodic payment                 $ 709      
Frequency of periodic payment                 Monthly      
Lease, interest expense                     $ (967,824) $ (748,474)
Operating lease rental expense                     $ 8,651 8,502
Operating lease expiration date                 May 31, 2017      
Lease agreement description                     The Company has negotiated and entered into a two-year amendment to that lease that commenced as of June 1, 2017 through May 31, 2019. The monthly rate from June 1, 2017 through May 31, 2018 was $709 per month and increased to $730 per month from June 1, 2018 through May 31, 2019.  
Capital Lease [Member]                        
Lease, interest expense                     $ 256 $ 0
Decahedron [Member]                        
Operating lease periodic payment         $ 2,430              
Frequency of periodic payment                     Monthly Monthly
Operating lease rental expense                     $ 39,762 $ 27,180
Operating lease expiration date         Oct. 24, 2021              
SkyPharm [Member]                        
Operating lease periodic payment       $ 1,432           $ 4,955    
Frequency of periodic payment       Monthly           Monthly    
Term of operating lease                   6 years    
SkyPharm [Member] | MediHelm S.A. [Member]                        
Operating lease rental expense                     $ 127,624 116,400
Total monthly operating lease amount                       10,310
SkyPharm [Member] | Additional space [Member]                        
Operating lease periodic payment           $ 2,091 $ 916          
Frequency of periodic payment           Monthly Monthly          
SkyPharm [Member] | First Floor [Member]                        
Operating lease periodic payment               $ 916        
Frequency of periodic payment               Monthly        
SkyPharm [Member] | April 18, 2018 [Member] | Advisory Agreement [Member]                        
Term of operating lease                     10 years  
Annually operating lease amount                     $ 104,000  
Amplerissimo [Member]                        
Operating lease periodic payment                     $ 110  
Frequency of periodic payment                     Monthly  
Operating lease rental expense                     $ 1,183 $ 1,492
Operating lease renewal date                     Jul. 31, 2018  
Cosmofarm [Member]                        
Frequency of periodic payment                     Monthly  
Operating lease rental expense                     $ 1,654  
Operating lease expiration date                     Sep. 30, 2018  
Term of operating lease                     10 years  
Total monthly operating lease amount                     $ 3,809  
Neos Kosmos [Member]                        
Frequency of periodic payment                     Monthly  
Operating lease rental expense                     $ 457  
Operating lease expiration date                     May 01, 2017  
Term of operating lease                     3 years  
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | On October 1, 2016 [Member] | Intellectual property sale agreement [Member]                        
Operating lease periodic payment                     $ 1,500  
Common stock shares reserved                     200,000  
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | On October 1, 2016 [Member] | Intellectual property sale agreement [Member] | Conclusion of Preclinical Trials [Member]                        
Common stock shares reserved                     50,000  
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | On October 1, 2016 [Member] | Intellectual property sale agreement [Member] | conclusion of Phase I testing [Member]                        
Common stock shares reserved                     50,000  
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | On October 1, 2016 [Member] | Intellectual property sale agreement [Member] | Conclusion of Phase III testing [Member]                        
Common stock shares reserved                     50,000  
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | On October 1, 2016 [Member] | Intellectual property sale agreement [Member] | Conclusion of Phase II testing [Member]                        
Common stock shares reserved                     50,000  
Private Placement [Member]                        
Commitments and contingencies description   (1) a cash commission of 6% of the total gross proceeds for two named investors (2) a cash commission of 4% of total gross proceeds from five named investors and (3) excluding the five named investors in “(2)” a cash commission equal to 8% of the total gross proceeds from the Offering and the issuance to the Agent or its designees of warrants covering 8% of the shares of common stock issued or issuable by the Company in the Offering. Additionally, the Agent will receive a cash fee of 8% payable within 5 business days, but only in the event of, the receipt by the Company of any cash proceeds from the exercise of any warrants with an expiration equal to or less than 24 months sold in the Offering.                    
Cash commission description In connection with the Company’s September 4, 2018 Note offering, the Agent received a cash commission for this transaction of $140,000, equal to seven (7%) percent of the total gross proceeds of the offering and the issuance of five-year warrants to purchase seven (7%) percent of the shares of Common Stock issued or issuable in this offering (excluding shares of Common Stock issuable upon exercise of any Warrants issued to investors, or 26,056 shares); however, will receive seven (7%) percent of any cash proceeds received from the exercise of any Warrants sold in the offering with an expiration equal to or less than twenty-four (24) months. The Warrants are exercisable six (6) months after the date of issuance, or March 4, 2019.   In connection with the Company’s November 16, 2017 Note offering, the Agent received a cash commission of $240,000, equal to eight (8%) percent of the total gross proceeds of the offering and the issuance of five-year warrants to purchase eight (8%) percent of the shares of Common Stock issued or issuable in the offering (excluding shares of Common Stock issuable upon exercise of any Warrants issued to investors, or 53,600 shares); however, will receive eight (8%) percent of any cash proceeds received from the exercise of any Warrants sold in the offering with an expiration equal to or less than twenty-four (24) months. The Warrants are exercisable six (6) months after the date of issuance, or as of May 16, 2018.